Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 1;75(4):503-509.
doi: 10.1001/jamaneurol.2017.4243.

When Do α-Synucleinopathies Start? An Epidemiological Timeline: A Review

Affiliations
Review

When Do α-Synucleinopathies Start? An Epidemiological Timeline: A Review

Rodolfo Savica et al. JAMA Neurol. .

Erratum in

  • Error in Byline.
    [No authors listed] [No authors listed] JAMA Neurol. 2018 Sep 1;75(9):1156. doi: 10.1001/jamaneurol.2018.1257. JAMA Neurol. 2018. PMID: 29799943 Free PMC article. No abstract available.

Abstract

Importance: This article reviews the epidemiological evidence of features of α-synucleinopathies that precede clinical onset of disease, proposes a clinical timeline, and attempts to define the different premotor and clinical phenotypes associated with α-synucleinopathies.

Observations: The pathological hallmarks of the α-synucleinopathies (Parkinson disease, Parkinson disease dementia, dementia with Lewy bodies, and multisystem atrophy) begin years before a clinical diagnosis. Epidemiologic studies support the long gap between pathology and symptoms and suggest that certain nonmotor conditions (constipation, anxiety, and rapid eye movement sleep behavior disorder) precede the traditional motor Parkinson disease phenotype by long intervals.

Conclusions and relevance: Characterizing the temporal onset of these conditions will help to better recognize the premotor phase of the α-synucleinopathies and specific clinical phenotypes and will guide the search for predictive biomarkers and risk or protective factors for Parkinson disease and other synucleinopathies.

PubMed Disclaimer

Comment in

MeSH terms

Substances